SecBot SecBot
8-K ·Filed Nov 5, 2026

VERA

Vera Therapeutics, Inc.
BULLISH
Impact 6/10
Horizonmonths Processed11d 8h ago SEC0001193125-26-449780
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

Monitor FDA review of the sBLA for full approval, expected in mid-2027, and the pace of TRUTAKNA patient starts and revenue ramp in Q4 2026 and Q1 2027. The European MAA submission planned for Q1 2027 is a secondary catalyst.

DirectionBullish
Confidencehigh
Horizonmonths

TRUTAKNA

▲ Bullish Named in this 8-K
Impact
Phase
Approved (Accelerated Approval)
Time to market
Already FDA-approved (July 7, 2026) — launched commercially; confirmatory full-approval data expected Q3 2026
Next catalyst
None dated

What to watchThe FDA approval is already priced in (modest +6.8% move on the day). The real binary catalysts ahead are the ORIGIN 3 eGFR confirmatory data (Q3 2026) and commercial launch execution metrics. Watch pricing/reimbursement decisions, early prescription uptake, and whether the confirmatory eGFR data supports full approval. The IgAN market is getting crowded (Tarpeyo, Filspari, Fabhalta, Vanrafia, Voyxact), so differentiation on convenience (at-home autoinjector) and upstream mechanism (dual BAFF/APRIL) will determine commercial success.

Price Chart

Loading chart...

Executive Summary

Vera Therapeutics reported Q3 2026 net product revenue of $10.3 million from the TRUTAKNA launch, its first revenue quarter, with approximately 700 Patient Start Forms received. Net loss widened to $93.7 million ($1.30 per share) from $80.3 million ($1.26 per share) a year ago, driven by $61.4 million in SG&A expenses for the commercial launch. The company completed its sBLA submission for full FDA approval of TRUTAKNA, with a decision expected in mid-2027.

Key Financial Metrics

EPS
−$1.30
Revenue
$10.3M
est $3.3M · +211.4%

Key Facts

  • First-ever product revenue of $10.3 million from TRUTAKNA launch in Q3 2026
  • Approximately 700 Patient Start Forms received since accelerated approval on July 7, 2026
  • Completed sBLA submission to FDA on November 3, 2026 for full approval of TRUTAKNA
  • ORIGIN 3 final efficacy analysis showed stabilization of kidney function and 76% reduction in risk of composite kidney disease progression
  • Net loss of $93.7 million ($1.30 per share) vs $80.3 million ($1.26 per share) in Q3 2025
  • Cash, cash equivalents and marketable securities of $384 million as of September 30, 2026; pro forma $459 million including $75 million drawn in late October
  • Up to $350 million remains available under debt facility

Financial Impact

First product revenue of $10.3 million in Q3 2026; net loss of $93.7 million; cash position of $384 million ($459 million pro forma)

revenuenet losscash position

Risk Factors

  • Full FDA approval is contingent on sBLA review and may not be granted
  • Commercial launch is early; revenue trajectory and payer coverage remain unproven at scale
  • Net loss and cash burn are increasing as SG&A spending ramps for the launch

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-449780
Document: vera-20261105.htm0001193125-26-449780
Document: 0001193125-26-449780-index-headers.html0001193125-26-449780
Document: 0001193125-26-449780-index.html0001193125-26-449780
Document: 0001193125-26-449780.txt0001193125-26-449780
8-K Data (Synthetic)0001193125-26-449780

Track record

25 reports on VERA

Performance horizon

13 of 14 bullish or bearish reports moved the stock their way by T+5. Best: +36.47% at T+20 after the Jun 2, 2026 report. 14 of 14 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $27.55 Now $26.97 −2.11% settles Nov 23
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $28.15 Now $26.97 −4.19% settles Nov 23
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $28.15 Now $26.97 −4.19% settles Nov 23
  4. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $30.03 Now $26.97 −10.19% settles Nov 17
  5. Nov 5, 202611d ago 8-K Bullish 6/10 Viewing No price data
  6. Nov 5, 202611d ago Press Release Bullish 6/10 Entry $29.79 to $28.10 Now $26.97 −9.45% ▼ −5.66% −8.25% vs SPY
  7. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $31.97 to $30.48 Now $26.97 −15.64% ▼ −4.66% −3.75% vs SPY
  8. Oct 22, 202625d ago Press Release Bullish 8/10 Entry $29.05 to $30.53 Now $26.97 −7.16% ▲ +5.09% +4.39% vs SPY
  9. Sep 15, 20268w ago 8-K Bullish 8/10 Entry $33.67 to $34.00 Now $26.97 −19.90% ▲ +0.98% +0.16% vs SPY
  10. Aug 10, 202614w ago 8-K Neutral 5/10 No price data
Showing 10 of 25

US Market Status

Market Closed · Opens in 8h 44m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026